Kidney International Corrects Missing Supplementary Data in Precision Nephrology Study
A corrigendum in Kidney International has restored missing information in the supplementary materials for a precision nephrology study on minimal change disease and focal segmental glomerulosclerosis. The correction is narrow but important: the first two columns of Supplementary Table S2, which had been accidentally deleted, are now included again in the online material.
In a paper built around biologic variability in tumor necrosis factor signaling, even a small formatting error can complicate interpretation. Supplementary tables often carry the granular data that support subgroup definitions, biomarker assignments, and downstream mechanistic analyses. When columns disappear from that framework, readers lose part of the evidentiary chain that connects the main text to the study’s deeper analytic structure.
The corrected record does not alter the study’s central claim on its face. It restores the supporting dataset.
Why a Supplementary Table Correction Matters in Precision Nephrology
Precision nephrology depends on data density. Studies in this area often move beyond broad disease labels and into biologically defined subgroups, where treatment response, pathway activation, and disease behavior may vary even within the same histologic diagnosis. For disorders such as minimal change disease and focal segmental glomerulosclerosis, that level of detail matters because both conditions can present with overlapping nephrotic features while still reflecting different underlying biology.
A deleted column in a supplementary table can be more than an editorial nuisance. If the table contains categorical assignments, biomarker values, or analytic descriptors, its absence can interrupt the reader’s ability to trace how investigators arrived at a given conclusion. In translational nephrology, where tissue signatures and pathway activation patterns often inform hypothesis generation, the integrity of supplementary material is part of the scientific record, not an accessory.
This corrigendum addresses that gap directly by adding back the first two columns to Supplementary Table S2. No broader methodological revision is described in the correction itself, and no new clinical outcome data are introduced. The action is limited to data restoration.
Tumor Necrosis Factor Signaling and the Need for Clean Data Presentation
The parent study focused on variability in tumor necrosis factor activation across minimal change disease and focal segmental glomerulosclerosis. That biological framing places the work squarely in the current effort to move glomerular disease research from descriptive pathology toward pathway-based classification. TNF-mediated inflammation can influence podocyte injury, endothelial activation, and immune signaling, making it a plausible axis for disease stratification in proteinuric kidney disorders.
When a study aims to identify biologic variability, presentation errors in the underlying data can erode confidence even if the main findings remain unchanged. Researchers, reviewers, and clinicians often consult the supplementary tables to understand cohort composition, measurement structure, and the exact relationship between patient-level observations and reported conclusions. Missing columns can obscure those links.
This correction therefore serves a practical scientific function: it re-establishes the completeness of the record so the published analysis can be read as intended. For nephrologists and translational investigators, that matters because biomarker-driven work tends to be cumulative. One table may feed into a future validation study, a mechanistic experiment, or a treatment-stratification framework. If the original table is incomplete, the subsequent work inherits unnecessary uncertainty.
What the Corrigendum Does and Does Not Change
The correction is specific and limited. It states that the first two columns of Supplementary Table S2 on page 142 were accidentally deleted and have now been added back. No new hypothesis is introduced. No additional patient cohort is described. No outcome data are revised. The corrigendum functions as a record correction rather than a scientific reversal.
That distinction is important for readers who rely on journal archives to preserve a stable account of the literature. Corrections of this kind help maintain trust in both the paper and the journal, particularly when the article touches on mechanistic classification rather than routine descriptive epidemiology. In pathway-based kidney research, precision depends on details that are often tucked into supplementary files rather than the main results section.
A missing pair of columns may look minor in isolation. In a biomarker-rich paper, it can be enough to interrupt the logic of the analysis.
Reading the Correction in the Context of Glomerular Disease Research
The underlying topic remains clinically relevant because minimal change disease and focal segmental glomerulosclerosis continue to challenge nephrologists with overlapping phenotypes and variable response patterns. Studies that interrogate immune activation pathways are trying to explain why some patients behave differently despite similar biopsy labels. If TNF activation varies across these entities, the implication is that traditional histology alone may not fully capture the biology driving proteinuria and renal injury.
For that reason, the completeness of Supplementary Table S2 is not a trivial editorial matter. It supports the scientific audit trail for a study that sits at the intersection of renal pathology, immunobiology, and future treatment personalization. Clinicians reading this literature depend on precise reporting to judge whether a pathway signal is robust, whether a subgroup distinction is reproducible, and whether the data justify additional validation.
This corrigendum restores the table to that standard. It leaves the scientific question intact while repairing the supporting documentation around it.
The correction is limited to the supplementary file, and the broader clinical question—how best to use pathway activation to classify and eventually treat podocytopathies—still depends on the rigor of the original dataset and future validation work.